Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282169 | 0.89 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL10631898 | 0.89 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL27282170 | 0.82 | CYP19A1 (0.82) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL8697229 | 0.80 | CYP19A1 (0.55) | CYP19A1CYP3A4CYP3A5KCNA5 | |
| SCHEMBL913686 | 0.80 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP3A5KCNA5 | |
| Triphenylmethanol SCHEMBL1332873 | 0.80 | CYP19A1 (0.50) | CYP19A1CYP3A4 | |
| Triphenylmethanol SCHEMBL700 | 0.80 | CYP19A1 (0.50) | CYP19A1CYP3A4 | |
| Triphenylmethanol SCHEMBL456603 | 0.80 | CYP19A1 (0.50) | CYP19A1CYP3A4 | |
| SCHEMBL9651054 | 0.78 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL8870530 | 0.78 | CYP19A1 (0.66) | CYP19A1CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| EP-0240263-B1 | INDENOPYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1992-07-15 | — | — | EP | claimed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022174035-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-107616173-B | Composition containing ZJ10520 and pyrimidine bactericide | 浙江省化工研究院有限公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-0824314-A1 | EFFICACY ENHANCER FOR AGRICULTURAL CHEMICALS AND AGRICULTURAL CHEMICAL COMPOSITIONS | Kao Corporation (JP) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997031527-A1 | EFFICACY ENHANCER FOR AGRICULTURAL CHEMICALS AND AGRICULTURAL CHEMICAL COMPOSITIONS | KAO CORPORATION (JP) | 1997-09-04 | — | — | WO | disclosed |
| EP-0240263-B1 | INDENOPYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1992-07-15 | — | — | EP | disclosed |
| CN-1052665-A | The pyridinyl carbamates compound, and preparation method thereof and the Biocidal composition that is used to prevent and treat harmful organisms that contains them | ISHIHARA SANGYO KAISHA (JP) | 1991-07-03 | — | — | CN | disclosed |
| CN-1036879-A | BIOCIDE COMPOSITIONS | ISHIHARA SANGYO KAISHA (JP) | 1989-11-08 | — | — | CN | disclosed |
| EP-0240263-A2 | Indenopyrimidine derivatives | ELI LILLY AND COMPANY (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4062959-A | N-methyl-imidazole derivatives for treating mycotic infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-13 | — | — | US | disclosed |
| US-3980780-A | N-Methyl-imidazole derivatives for treating mycotic infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
| US-3934014-A | N-methyl-imidazole derivatives as anti-mycotic agents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | CYP19A1 2730/4885CYP3A4 1010/4885CYP3A5 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.